Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Kangmei Pharmaceutical Co stock

600518.SS
CNE0000017M1

Price

1.98
Today +/-
-0.00
Today %
-0.50 %
P

Kangmei Pharmaceutical Co stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Kangmei Pharmaceutical Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Kangmei Pharmaceutical Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Kangmei Pharmaceutical Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Kangmei Pharmaceutical Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Kangmei Pharmaceutical Co Stock Price History

DateKangmei Pharmaceutical Co Price
11/1/20241.98 undefined
10/31/20241.99 undefined
10/30/20242.02 undefined
10/29/20241.97 undefined
10/28/20242.04 undefined
10/25/20242.00 undefined
10/24/20242.02 undefined
10/23/20241.94 undefined
10/22/20241.85 undefined
10/21/20241.82 undefined
10/18/20241.84 undefined
10/17/20241.80 undefined
10/16/20241.84 undefined
10/15/20241.86 undefined
10/14/20241.90 undefined
10/11/20241.88 undefined
10/10/20241.92 undefined
10/9/20241.91 undefined
10/8/20242.10 undefined

Kangmei Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Kangmei Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Kangmei Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Kangmei Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Kangmei Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Kangmei Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Kangmei Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Kangmei Pharmaceutical Co’s growth potential.

Kangmei Pharmaceutical Co Revenue, EBIT and net profit per share

DateKangmei Pharmaceutical Co RevenueKangmei Pharmaceutical Co EBITKangmei Pharmaceutical Co Net Income
20234.87 B undefined172.03 M undefined102.52 M undefined
20224.18 B undefined-1.01 B undefined-2.69 B undefined
20214.15 B undefined-4.02 B undefined7.92 B undefined
20205.41 B undefined-23.46 B undefined-27.74 B undefined
201911.45 B undefined-1.83 B undefined-4.66 B undefined
201817.07 B undefined2.49 B undefined374 M undefined
201717.58 B undefined3.92 B undefined2.15 B undefined
201621.64 B undefined4.58 B undefined3.34 B undefined
201518.07 B undefined3.57 B undefined2.76 B undefined
201415.95 B undefined3.04 B undefined2.29 B undefined
201313.36 B undefined2.48 B undefined1.88 B undefined
201211.17 B undefined1.96 B undefined1.44 B undefined
20116.08 B undefined1.3 B undefined1.01 B undefined
20103.31 B undefined853 M undefined716 M undefined
20092.38 B undefined598 M undefined502 M undefined
20081.73 B undefined332 M undefined295 M undefined
20071.29 B undefined240 M undefined179 M undefined
2006826 M undefined167 M undefined100 M undefined
2005585 M undefined120 M undefined73 M undefined
2004553 M undefined115 M undefined71 M undefined

Kangmei Pharmaceutical Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)SHARES (B)DOCUMENTS
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0.350.380.410.460.550.590.831.291.732.383.316.0811.1713.3615.9518.0721.6417.5817.0711.455.414.154.184.87
-8.247.8712.9019.185.7941.2056.6633.4637.6439.2183.7783.6019.6519.3913.2819.79-18.77-2.92-32.93-52.72-23.280.6716.60
20.1719.9524.8227.3730.3830.7728.8125.7326.6933.1135.9629.7324.9525.9025.9728.0529.4238.0731.287.42-375.33-11.257.8522.20
0.070.080.10.130.170.180.240.330.460.791.191.812.793.464.145.076.376.695.340.85-20.31-0.470.331.08
0.040.050.070.090.120.120.170.240.330.60.851.31.962.483.043.574.583.922.49-1.83-23.46-4.02-1.010.17
12.2212.3416.3018.3220.8020.5120.2218.5519.2225.1625.7821.3017.5618.5419.0719.7521.1622.3014.58-15.99-433.56-96.82-24.163.53
0.030.030.040.050.070.070.10.180.30.50.721.011.441.882.292.763.342.150.37-4.66-27.747.92-2.690.1
-16.0051.7215.9139.222.8236.9979.0064.8070.1742.6340.3643.3830.4621.6020.6021.15-35.63-82.60-1,346.26495.07-128.54-133.95-103.79
1.682.252.252.252.252.253.13.223.63.833.994.314.44.44.44.45.025.544.934.714.9413.8613.7913.79
------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Kangmei Pharmaceutical Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Kangmei Pharmaceutical Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (B)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (B)INTANGIBLE ASSETS (B)GOODWILL (M)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (B)UNREAL. GAINS/LOSSES (k)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                               
0.010.160.070.110.090.050.711.521.481.992.766.326.118.59.9915.8227.334.211.840.50.552.351.430.96
0.050.060.070.070.080.080.090.110.160.280.460.681.331.712.232.553.14.996.073.672.411.361.962.03
0000000000.020.040.150.10.250.280.460.416.7111.4310.749.621.140.970.94
0.060.080.10.10.130.120.210.270.571.031.141.913.563.797.379.812.6235.2533.8531.419.043.192.752.64
0.0100.010.010.0100.20.230.070.170.20.40.410.40.790.831.021.231.70.690.280.250.270.24
0.120.310.240.290.310.261.212.132.283.484.619.4611.5114.6420.6529.4544.4652.3954.8847.0121.98.287.386.81
0.080.180.320.340.410.410.640.871.281.611.83.364.064.624.774.966.168.0611.4911.449.234.674.193.9
00000000.110.130.180.260.260.280.820.861.091.261.763.753.533.382.242.772.81
0000000000000000000001.050.890
0.030.020.060.060.130.120.070.120.520.871.351.951.881.81.071.051.831.992.142.031.310.580.530.49
000000000611611701701732243054565532618137106.35106.35106.35
00.010.010.010.010.010000.010.030.050.060.20.311.250.660.540.620.490.350.170.180.17
0.110.210.390.420.550.540.711.111.932.733.65.786.457.617.238.6610.3612.918.2617.5714.318.828.677.47
0.230.520.630.70.860.791.923.244.216.228.2115.2417.9622.2527.8838.1154.8265.2973.1464.5936.2117.1116.0614.28
                                               
0.050.070.070.070.110.110.220.510.761.691.692.22.22.22.24.44.957.947.947.947.9413.8613.8613.86
00.230.230.230.20.210.61.41.471.821.824.744.744.754.763.6611.3411.6111.6511.5511.5818.7818.7818.78
0.050.070.110.140.210.260.340.450.680.761.412.313.645.086.797.7310.019.256.781.37-26.36-21.79-24.48-24.37
000000000000002.972.982.96-0-0-0-0-0-0-0
0000000000000000000000391.18152.09
0.10.370.410.440.510.571.162.362.924.274.939.2510.5812.0316.7218.7729.2628.826.3720.86-6.8410.868.178.27
0.030.040.040.040.040.050.050.060.090.180.270.450.760.981.391.441.692.083.173.773.32.022.532.21
0000000.010.010.010.020.020.10.140.210.230.460.540.861.030.872.471.21.270.74
0.020.020.010.010.010.010.020.03-0.010.060.110.160.552.782.617.159.483.974.944.54.391.670.580.66
0.040.080.120.160.20.160.50.780.570.861.1412.12.293.824.828.3216.3919.3214.083.820.031.021.03
00.0200.05000.20000.10.340.20.880.20.0102.504.68.850.040.040.04
0.090.150.170.260.260.220.770.880.661.121.632.053.757.138.2513.8820.0325.828.4627.8222.824.955.444.68
0.0200.0500.080000.620.811.623.653.312.72.54.894.898.3117.4615.0119.420.150.20.19
000000000000003500000055.5351.68
0.020000.01000.010.010.020.040.290.310.390.410.50.532.671.11.11.040.992.492.28
0.0400.0500.09000.010.640.831.653.943.633.092.915.395.4210.9818.5716.1120.451.142.742.52
0.130.150.220.260.340.220.770.881.291.953.285.997.3810.2211.1619.2725.4436.7847.0343.9443.276.098.187.2
0.230.520.630.710.850.791.923.244.216.228.2115.2417.9622.2527.8838.0354.765.5873.464.836.4316.9516.3615.47
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Kangmei Pharmaceutical Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Kangmei Pharmaceutical Co's financial health and stability.

Assets

Kangmei Pharmaceutical Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Kangmei Pharmaceutical Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Kangmei Pharmaceutical Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Kangmei Pharmaceutical Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (B)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (B)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
000000000000000000007.92-2.69
00000000000000000000603359
0000000000000000000016620
-18-22-26-21-27-31-27-50-121-287-41-542-519-416-844-818-4,474-1,889-1,499-1,401-271-823
000000000000000000006.160.8
0000000000000000000001,000
-24-32-49-62-75-78-111-124-111-273-489-567-783-1,101-1,404-1,493-1,809-1,878-537-295-235-284
0.020.050.080.080.130.070.1600.120.670.581.011.671.130.511.6-4.840.312.881.030.21-0.75
-116-202-48-150-22-413-328-693-724-768-2,321-1,405-703-682-1,374-1,567-2,147-4,593-473-301-171-48
-132-202-48-150-22-413-404-669-764-856-2,284-1,381-735-768-1,443-1,986-1,882-4,650-168832-36-46
-0.0200000-0.080.02-0.04-0.090.040.02-0.03-0.09-0.07-0.420.27-0.060.31.130.140
0000000000000000000000
0.040.080.040.07-0.130.34-0.320.680.371.112.090.562.2-0.777.855.568.415.12-1.53-0.850.030
000000000000000000001.80
0.260.060.010.06-0.161.011.050.631.150.965.270.151.431.146.7611.836.151.99-4.05-1.881.77-0.12
0.2500000.681.4100.8903.430-0.012.960.038.21-0.04-0.110.0301.75-0.12
-18-19-27-14-31-16-35-46-105-151-249-412-759-1,046-1,120-1,932-2,223-3,015-2,546-1,032-130
0.210.020.190.150.190.841.110.140.8624.671.895.344.168.5815.370.871.723.592.722.67-0.55
-100.8-148.929.4-71.7110.7-345.1-165.6-690.1-604.7-98.8-1,746-396.6970.6450.1-865.835.8-6,987.8-4,287.72,408.8729.742.58-798.08
0000000000000000000000

Kangmei Pharmaceutical Co stock margins

The Kangmei Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Kangmei Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Kangmei Pharmaceutical Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Kangmei Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Kangmei Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Kangmei Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Kangmei Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Kangmei Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Kangmei Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Kangmei Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Kangmei Pharmaceutical Co Margin History

Kangmei Pharmaceutical Co Gross marginKangmei Pharmaceutical Co Profit marginKangmei Pharmaceutical Co EBIT marginKangmei Pharmaceutical Co Profit margin
202322.22 %3.53 %2.1 %
20227.86 %-24.18 %-64.32 %
2021-11.26 %-96.82 %190.68 %
2020-375.33 %-433.56 %-512.49 %
20197.42 %-15.99 %-40.72 %
201831.28 %14.58 %2.19 %
201738.07 %22.3 %12.23 %
201629.42 %21.16 %15.43 %
201528.05 %19.75 %15.26 %
201425.97 %19.07 %14.33 %
201325.9 %18.54 %14.07 %
201224.95 %17.56 %12.91 %
201129.73 %21.3 %16.53 %
201035.96 %25.78 %21.64 %
200933.11 %25.16 %21.12 %
200826.69 %19.22 %17.08 %
200725.73 %18.55 %13.83 %
200628.81 %20.22 %12.11 %
200530.77 %20.51 %12.48 %
200430.38 %20.8 %12.84 %

Kangmei Pharmaceutical Co Stock Sales Revenue, EBIT, Earnings per Share

The Kangmei Pharmaceutical Co earnings per share therefore indicates how much revenue Kangmei Pharmaceutical Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Kangmei Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Kangmei Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Kangmei Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Kangmei Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Kangmei Pharmaceutical Co Revenue, EBIT and net profit per share

DateKangmei Pharmaceutical Co Sales per ShareKangmei Pharmaceutical Co EBIT per shareKangmei Pharmaceutical Co Earnings per Share
20230.35 undefined0.01 undefined0.01 undefined
20220.3 undefined-0.07 undefined-0.2 undefined
20210.3 undefined-0.29 undefined0.57 undefined
20201.1 undefined-4.75 undefined-5.62 undefined
20192.43 undefined-0.39 undefined-0.99 undefined
20183.46 undefined0.5 undefined0.08 undefined
20173.17 undefined0.71 undefined0.39 undefined
20164.31 undefined0.91 undefined0.67 undefined
20154.11 undefined0.81 undefined0.63 undefined
20143.63 undefined0.69 undefined0.52 undefined
20133.04 undefined0.56 undefined0.43 undefined
20122.54 undefined0.45 undefined0.33 undefined
20111.41 undefined0.3 undefined0.23 undefined
20100.83 undefined0.21 undefined0.18 undefined
20090.62 undefined0.16 undefined0.13 undefined
20080.48 undefined0.09 undefined0.08 undefined
20070.4 undefined0.07 undefined0.06 undefined
20060.27 undefined0.05 undefined0.03 undefined
20050.26 undefined0.05 undefined0.03 undefined
20040.25 undefined0.05 undefined0.03 undefined

Kangmei Pharmaceutical Co business model

Kangmei Pharmaceutical Co. Ltd is a Chinese company that was founded in 1997. It is headquartered in the city of Lianyungang in the Jiangsu province and has been listed on the Shanghai Stock Exchange since 2001. With a market capitalization of over 15 billion US dollars, it is one of the leading pharmaceutical companies in the country. The company's business model is based on the development, production, and distribution of pharmaceutical products and medical devices. It is divided into several divisions, including drugs for colds, diabetes, cancer, and other diseases, dietary supplements, contrast agents for X-rays, as well as medical devices such as infusion pumps, blood pressure monitors, and ultrasound machines. Kangmei has focused heavily on the domestic market in recent years and is present in all provinces of China. It operates over 30 subsidiaries throughout the country and has more than 10,000 employees. The company is committed to improving healthcare in China and developing innovative products for the domestic market. One of Kangmei's most well-known drugs is "Ganmaoling Granule," a traditional Chinese medicine for treating colds and flu. It has been in production for over 30 years and is very popular in China. Kangmei also produces various drugs for the treatment of diabetes, including insulin preparations and oral medications. Another important area for Kangmei is the development of cancer drugs. The company specializes in researching and developing innovative therapies for various types of cancer. It has introduced several products to the market that can be used in the treatment of lung cancer, breast cancer, and other tumors. In addition to its pharmaceutical products, Kangmei has also developed a range of dietary supplements, such as "Qingkailing Capsules," which are made from natural ingredients and are intended to strengthen the immune system. These products are very popular in China and also contribute to Kangmei's diversification of its business operations. Kangmei has also specialized in the production of medical devices. It has developed a wide range of products such as infusion pumps, dialysis machines, and ultrasound devices. These devices are in high demand in China and other countries around the world, such as Africa and Latin America. Overall, Kangmei has established a strong presence in the Chinese pharmaceutical and medical market and is well-positioned to benefit from the strong growth of the healthcare sector in China. The company focuses on innovation and invests heavily in research and development of new products. It aims to play a leading role in the Chinese healthcare industry while contributing to the improvement of healthcare services. Kangmei Pharmaceutical Co is one of the most popular companies on Eulerpool.com.

Kangmei Pharmaceutical Co SWOT Analysis

Strengths

Kangmei Pharmaceutical Co Ltd has several strengths that contribute to its success within the pharmaceutical industry. Firstly, the company has a strong brand presence in the market, which helps build customer trust and loyalty. Secondly, Kangmei Pharmaceutical boasts a diverse portfolio of products, ranging from over-the-counter medicines to prescription drugs, allowing them to cater to a wide range of consumer needs. Additionally, the company has established strategic partnerships with key stakeholders, including hospitals, distributors, and research institutions, enhancing their market reach and competitiveness.

Weaknesses

In spite of its strengths, Kangmei Pharmaceutical faces certain weaknesses that could hinder its growth prospects. One key weakness is its limited international presence, primarily focusing on the domestic Chinese market. This narrow geographical reach may impact the company's potential for global expansion in an increasingly interconnected world. Furthermore, the company relies heavily on third-party suppliers for raw materials, making them susceptible to disruptions in the supply chain, resulting in potential production delays and increased costs.

Opportunities

There are several opportunities that Kangmei Pharmaceutical can leverage to drive further growth. The growing demand for pharmaceutical products in emerging markets presents a significant opportunity for expansion. By targeting these high-growth regions and establishing a solid international presence, Kangmei Pharmaceutical can tap into new revenue streams and diversify its customer base. Additionally, advancements in technology and digital healthcare solutions open doors for the company to enhance its product offerings and engage with customers in innovative ways.

Threats

With opportunities come threats, and Kangmei Pharmaceutical must be aware of potential challenges in the market. One notable threat is the increasing competition from both domestic and international pharmaceutical companies. This intensifying competition may put pressure on Kangmei Pharmaceutical to differentiate its products and maintain competitive pricing strategies. Additionally, the ever-changing regulatory landscape and stringent government policies in the pharmaceutical industry can pose challenges that the company must navigate effectively to ensure compliance and avoid penalties.

Kangmei Pharmaceutical Co Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Kangmei Pharmaceutical Co historical P/E ratio, EBIT multiple, and P/S ratio

Kangmei Pharmaceutical Co shares outstanding

The number of shares was Kangmei Pharmaceutical Co in 2023 — This indicates how many shares 13.788 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Kangmei Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Kangmei Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Kangmei Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Kangmei Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Kangmei Pharmaceutical Co stock splits

In Kangmei Pharmaceutical Co's history, there have been no stock splits.

Kangmei Pharmaceutical Co dividend history and estimates

In 2023, Kangmei Pharmaceutical Co paid a dividend amounting to 0 CNY. Dividend means that Kangmei Pharmaceutical Co distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Kangmei Pharmaceutical Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Kangmei Pharmaceutical Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Kangmei Pharmaceutical Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Kangmei Pharmaceutical Co Dividend History

DateKangmei Pharmaceutical Co Dividend
20190.02 undefined
20180.22 undefined
20170.19 undefined
20160.18 undefined
20150.15 undefined
20140.16 undefined
20130.13 undefined
20120.03 undefined
20110.03 undefined
20100.02 undefined
20090.02 undefined
20080 undefined
20070 undefined
20060 undefined
20050.01 undefined
20040 undefined

Kangmei Pharmaceutical Co dividend payout ratio

In 2023, Kangmei Pharmaceutical Co had a payout ratio of 148.34%. The payout ratio indicates the percentage of the company's profits that Kangmei Pharmaceutical Co distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Kangmei Pharmaceutical Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Kangmei Pharmaceutical Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Kangmei Pharmaceutical Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Kangmei Pharmaceutical Co Payout Ratio History

DateKangmei Pharmaceutical Co Payout ratio
2023148.34 %
2022180.22 %
2021147.51 %
2020117.29 %
2019-2.27 %
2018275.88 %
201749.36 %
201626.63 %
201523.84 %
201431.31 %
201329.12 %
20129.48 %
201113.61 %
201012.17 %
200914.46 %
20083.13 %
20076.17 %
20065.67 %
200534.67 %
20045.67 %

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for Kangmei Pharmaceutical Co.

Kangmei Pharmaceutical Co latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/20120.08 0.09  (18.26 %)2012 Q4
9/30/20120.06 0.06  (1.17 %)2012 Q3
6/30/20120.09 0.06  (-25.37 %)2012 Q2
12/31/20110.1 0.08  (-23.81 %)2011 Q4
9/30/20110.05 0.04  (-8.47 %)2011 Q3
6/30/20110.06 0.04  (-28.09 %)2011 Q2
12/31/20100.03 0.03  (5.35 %)2010 Q4
9/30/20100.04 0.04  (-6.81 %)2010 Q3
12/31/20090.04 0.05  (15.29 %)2009 Q4
9/30/20090.01 0.02  (69.72 %)2009 Q3
1
2

Eulerpool ESG Scorecard© for the Kangmei Pharmaceutical Co stock

Eulerpool World ESG Rating (EESG©)

42/ 100

🌱 Environment

42

👫 Social

48

🏛️ Governance

37

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees55.07
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Kangmei Pharmaceutical Co shareholders

%
Name
Stocks
Change
Date
25.37733 % Guangdong Shennongshi Enterprise Management Partnership LP3,509,413,78806/30/2024
4.72348 % China Construction Bank Corp653,206,90906/30/2024
2.25199 % Kangmei Industrial Investment Holdings Co., Ltd.311,426,409-140,793,3736/30/2024
1.34754 % China Everbright Bank Co., Ltd.186,349,99706/30/2024
1.32612 % China Minsheng Banking Corp Ltd183,387,92106/30/2024
1.31477 % GF Fund Management Co., Ltd.181,818,18106/30/2024
1.07022 % Changan International Trust Company Ltd.148,000,00006/30/2024
0.84561 % HuaAn Future Asset Management (Shanghai) Co., Ltd.116,938,968-46,673,5976/30/2024
0.74873 % Shanghai Pudong Development Bank Co Ltd103,541,540103,541,5406/30/2024
0.00167 % Mellon Investments Corporation230,64009/30/2024
1
2
3

Kangmei Pharmaceutical Co Executives and Management Board

Mr. Guowei Liu(50)
Kangmei Pharmaceutical Co General Manager, Director (since 2020)
Compensation 1.5 M
Mr. Zhijian Lai(54)
Kangmei Pharmaceutical Co Chairman of the Board (since 2022)
Compensation 1.41 M
Mr. Guibo Gong(49)
Kangmei Pharmaceutical Co Chief Financial Officer, Deputy General Manager (since 2020)
Compensation 1.35 M
Mr. Yunfeng Zhou(41)
Kangmei Pharmaceutical Co Chief Compliance Officer, Deputy General Manager, Secretary of the Board, Chief Investor Relations Officer
Compensation 1.35 M
Mr. Qiyun Chen(45)
Kangmei Pharmaceutical Co General Manager - Pharmaceutical Business Division, General Manager -Traditional Chinese Medicine and Smart Pharmacy Division, Deputy General Manager
Compensation 1.17 M
1
2
3
4

Kangmei Pharmaceutical Co Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
NOVA Technology A Stock
NOVA Technology A
SupplierCustomer0,890,930,67-0,25-0,35
1

Most common questions regarding Kangmei Pharmaceutical Co

What values and corporate philosophy does Kangmei Pharmaceutical Co represent?

Kangmei Pharmaceutical Co Ltd is a renowned company in the pharmaceutical industry. With a strong emphasis on integrity, innovation, and customer satisfaction, Kangmei Pharmaceutical Co Ltd prides itself on its commitment to providing high-quality products and services. The company believes in maintaining a harmonious relationship between employees, customers, and shareholders. Through continuous research and development, Kangmei Pharmaceutical Co Ltd strives to introduce cutting-edge technologies and products to improve global healthcare. By promoting humanitarian principles and sustainable growth, Kangmei Pharmaceutical Co Ltd aims to contribute to the betterment of society while ensuring profitability and long-term success.

In which countries and regions is Kangmei Pharmaceutical Co primarily present?

Kangmei Pharmaceutical Co Ltd primarily operates in China, with a strong presence throughout the country. The company's headquarters is located in Shenzhen, Guangdong Province, China. Kangmei Pharmaceutical Co Ltd has a vast distribution network that covers various regions within China, including major cities and provinces. With a focus on the domestic market, Kangmei Pharmaceutical Co Ltd has established numerous production bases nationwide, ensuring its presence and accessibility across different regions of China.

What significant milestones has the company Kangmei Pharmaceutical Co achieved?

Kangmei Pharmaceutical Co Ltd, a leading pharmaceutical company, has achieved several significant milestones. The company has demonstrated remarkable growth in recent years, expanding its product portfolio and market presence. Kangmei Pharmaceutical Co Ltd has successfully developed and launched innovative drugs, contributing to advancements in medical treatments. Additionally, the company has established strategic partnerships and collaborations, enhancing its research and development capabilities. With a commitment to quality and innovation, Kangmei Pharmaceutical Co Ltd has gained recognition in the industry and has become a trusted name in the pharmaceutical sector.

What is the history and background of the company Kangmei Pharmaceutical Co?

Kangmei Pharmaceutical Co Ltd, a renowned Chinese company, was founded in 1997. With more than two decades of experience, Kangmei Pharmaceutical has become a leading player in the pharmaceutical industry. The company specializes in the research, development, production, and distribution of various healthcare products, including traditional Chinese medicine, chemical pharmaceuticals, biological products, and medical devices. Kangmei Pharmaceutical focuses on innovation, quality, and efficiency, striving to provide safe and effective medical solutions to improve people's health and well-being. The company has built a strong reputation both domestically and internationally for its commitment to scientific research, stringent quality standards, and sustainable development practices. With a vast product portfolio and a global presence, Kangmei Pharmaceutical continues to pursue technological advancements and strategic collaborations to further strengthen its position in the pharmaceutical market.

Who are the main competitors of Kangmei Pharmaceutical Co in the market?

The main competitors of Kangmei Pharmaceutical Co Ltd in the market include companies such as Shanghai Pharmaceuticals Holding Co Ltd, China Resources Sanjiu Medical & Pharmaceutical Co Ltd, and Jiangsu Hengrui Medicine Co Ltd.

In which industries is Kangmei Pharmaceutical Co primarily active?

Kangmei Pharmaceutical Co Ltd primarily operates in the pharmaceutical industry.

What is the business model of Kangmei Pharmaceutical Co?

The business model of Kangmei Pharmaceutical Co Ltd revolves around pharmaceutical manufacturing, sales, and distribution. As a leading Chinese pharmaceutical company, Kangmei focuses on research, production, and marketing of a wide range of medicinal products. With a comprehensive product portfolio covering areas such as Chinese herbal medicine, prescription drugs, and health products, Kangmei delivers accessible and affordable healthcare solutions to consumers. By emphasizing technological innovation, quality control, and strategic partnerships, Kangmei seeks to constantly improve its product offering, expand market reach, and enhance overall customer satisfaction.

What is the P/E ratio of Kangmei Pharmaceutical Co 2024?

The P/E ratio cannot be calculated for Kangmei Pharmaceutical Co at the moment.

What is the P/S ratio of Kangmei Pharmaceutical Co 2024?

The P/S cannot be calculated for Kangmei Pharmaceutical Co currently.

What is the Quality Investing of Kangmei Pharmaceutical Co?

The Quality Investing for Kangmei Pharmaceutical Co is 2/10.

What is the revenue of Kangmei Pharmaceutical Co 2024?

The revenue cannot currently be calculated for Kangmei Pharmaceutical Co.

How high is the profit of Kangmei Pharmaceutical Co 2024?

The profit cannot currently be calculated for Kangmei Pharmaceutical Co.

What is the business model of Kangmei Pharmaceutical Co

Kangmei Pharmaceutical Co Ltd is a Chinese company that was founded in 1997 and is headquartered in Lianyungang City. The company operates in the pharmaceutical industry and manufactures a wide range of drugs, dietary supplements, and medical devices. The business model of Kangmei Pharmaceutical consists of various divisions that focus on different product categories. The main business areas are the production of traditional Chinese medicines, modern pharmaceutical products, medical devices, and health products. All of these divisions are the result of ongoing research and development to ensure the quality and efficacy of the products. Kangmei's traditional Chinese medicines are highly popular and well-known in China. These are plant extracts that have been used in Chinese medicine for centuries to treat diseases. These medicines are available in various forms, including powders, tablets, capsules, and liquids. Kangmei Pharmaceutical also produces a variety of modern pharmaceutical products made from synthetic compounds. These products can be found in all major therapy areas such as cancer, cardiovascular diseases, diabetes, and infectious diseases. The company is very active in the Chinese market but is also exploring opportunities to distribute its products internationally. In addition to manufacturing drugs, Kangmei also produces medical devices. These are instruments and equipment used in diagnosis and therapy to improve the patient's health condition. There are also medical devices used in the fitness industry. Finally, Kangmei Pharmaceutical also produces a range of dietary supplements and health products. These products are naturally derived from plants and other natural sources and help promote health and prevent diseases. Kangmei's products are of high quality and meet the requirements of regulatory authorities such as the US FDA and the European EMA. Furthermore, the company is committed to researching products that meet the needs of people worldwide. It collaborates with leading universities and research institutes to find innovative solutions to existing health problems. Overall, Kangmei Pharmaceutical has a wide product portfolio catering to different markets and customer needs. Through continuous innovation and dedicated research, the company strives to improve the health of people worldwide.

What is the Kangmei Pharmaceutical Co dividend?

Kangmei Pharmaceutical Co pays a dividend of 0 CNY distributed over payouts per year.

How often does Kangmei Pharmaceutical Co pay dividends?

The dividend cannot currently be calculated for Kangmei Pharmaceutical Co or the company does not pay out a dividend.

What is the Kangmei Pharmaceutical Co ISIN?

The ISIN of Kangmei Pharmaceutical Co is CNE0000017M1.

What is the Kangmei Pharmaceutical Co ticker?

The ticker of Kangmei Pharmaceutical Co is 600518.SS.

How much dividend does Kangmei Pharmaceutical Co pay?

Over the past 12 months, Kangmei Pharmaceutical Co paid a dividend of 0.02 CNY . This corresponds to a dividend yield of about 1.14 %. For the coming 12 months, Kangmei Pharmaceutical Co is expected to pay a dividend of 0 CNY.

What is the dividend yield of Kangmei Pharmaceutical Co?

The current dividend yield of Kangmei Pharmaceutical Co is 1.14 %.

When does Kangmei Pharmaceutical Co pay dividends?

Kangmei Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of June, July, August, September.

How secure is the dividend of Kangmei Pharmaceutical Co?

Kangmei Pharmaceutical Co paid dividends every year for the past 0 years.

What is the dividend of Kangmei Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kangmei Pharmaceutical Co located?

Kangmei Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kangmei Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kangmei Pharmaceutical Co from 8/28/2019 amounting to 0.024 CNY, you needed to have the stock in your portfolio before the ex-date on 8/28/2019.

When did Kangmei Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 8/28/2019.

What was the dividend of Kangmei Pharmaceutical Co in the year 2023?

In the year 2023, Kangmei Pharmaceutical Co distributed 0 CNY as dividends.

In which currency does Kangmei Pharmaceutical Co pay out the dividend?

The dividends of Kangmei Pharmaceutical Co are distributed in CNY.

All fundamentals about Kangmei Pharmaceutical Co

Our stock analysis for Kangmei Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kangmei Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.